Industry Bulletins | December 7, 2022
C2N Diagnostics To Launch Sales In Early 2023 Of Its PrecivityAD2 Blood Test To Diagnose Alzheimer’s Disease
C2NDiagnostics,LLC (C2N), which develops advanced brain health diagnostics, plans to launch commercial sales in the first quarter of 2023 of its PrecivityAD2™ blood test to diagnose Alzheimer’s disease (AD). The test is expected to facilitate earlier and more accurate diagnosis of AD pathology. The test uses mass spectrometry-based measurements of two key plasma proteins implicated in the AD process: tau and amyloid beta.
The tau protein measured in the PrecivityAD2™blood test is expressed as a concentration ratio between two peptides that contain tau amino acid 217 known as the p-tau217 Ratio; one peptide is phosphorylated . . .